The purpose of the study is to evaluate whether a single administration of the psilocybin and trazodone combination, along with psychotherapeutic support, can improve symptoms of depression in adults with treatment-resistant depression over a period of one month. Participants will receive either the combination treatment or a placebo, and their progress will be monitored through various assessments. These assessments will include questionnaires and scales that measure the severity of depression symptoms, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory (BDI).

Throughout the study, participants will be observed for any changes in their condition, including potential side effects. The study aims to provide insights into the effectiveness of this new treatment approach and its impact on the quality of life for individuals with treatment-resistant depression. The trial will last for several months, with regular check-ins to assess the participants’ mental health and overall well-being.

Participants in the study will receive either the combination of ketamine and ECS or a placebo. The study will last for several weeks, during which participants will be monitored for changes in their depressive symptoms. The primary focus is to observe the short-term effects of the treatment over four weeks, with additional assessments to evaluate long-term effects and any impact on cognitive function, which refers to mental processes like thinking and memory.

The study aims to identify specific factors that determine how well patients respond to the treatment. This information could help tailor future treatments for individuals with treatment-resistant MDD, offering new hope for those who have not found relief with standard antidepressant medications. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of this study is to examine how well long-term maintenance treatment with ketamine works for keeping depression symptoms from coming back after an initial treatment period. The study is designed to compare different treatment approaches over time to see which one is most effective at preventing depression from returning. Participants will be divided into three different treatment groups to compare the results. The study will look at how long it takes for depression symptoms to come back after the initial treatment phase and after the last ketamine infusion, using a depression rating scale to measure symptom severity.

During the study, participants will receive ketamine infusions according to their assigned treatment group, with the treatment lasting up to 10 days in total. The maximum daily dose will be 150 milligrams, and the maximum total dose across all infusions will be 2700 milligrams. Throughout the study, doctors will monitor participants for any unwanted effects or reactions to the treatment through interviews, observations, questionnaires, and review of medical records. Women who could become pregnant must have a negative pregnancy test before starting the study and before each maintenance ketamine infusion, and must use highly effective birth control methods throughout their participation in the study.

The purpose of this study is to find out if taking 100 milligrams of DHEA daily along with continued standard antidepressant medication works better at reducing depression symptoms than taking placebo along with the same antidepressant medication. Participants will continue taking their regular antidepressant medicine, which could be medications such as SSRI, SNRI, tricyclic antidepressants, mirtazapine, or bupropion, and will additionally receive either DHEA or placebo tablets to take by mouth.

The study treatment will last for six months. During this time, depression symptoms will be measured using rating scales that help doctors understand how severe the depression is and whether it is getting better. The study will also look at whether participants respond to treatment, which means their depression symptoms are reduced by half, and whether they achieve remission, which means their depression symptoms become very mild. Other measurements will include quality of life, overall functioning, and various blood tests to check things like blood sugar and cholesterol levels. The study will also monitor any side effects and how well participants tolerate the treatment.

Participants in the study will take the medication orally. During the process, the use of music and professional support is evaluated to see how these elements influence the experience and the lasting effects of the treatment. The study monitors how symptoms change from the beginning of the process through a follow-up period of six weeks.

The purpose of this study is to find out whether using genetic testing before choosing an antidepressant medication leads to better results compared to the usual way doctors select these medications. The genetic testing looks at specific genes that can affect how a person’s body processes antidepressant medications and how well they might respond to treatment. The study will compare two groups of patients: one group will have their treatment chosen based on genetic test results along with other medical information, while the other group will receive treatment selected in the standard way without genetic testing. The study aims to see which approach helps patients feel better faster and with fewer side effects.

Participants will be followed for 16 weeks after starting their new antidepressant medication. During this time, they will have regular visits with their doctor to check how well the treatment is working and whether they are experiencing any side effects. The study will measure improvement in depression symptoms using questionnaires that ask about mood, energy, sleep, and other aspects of daily life. Doctors will also track how many times the medication needs to be changed or adjusted, how many doctor visits are needed, and whether any unwanted effects occur. The study will also look at the costs of both treatment approaches to see if genetic testing provides good value.

The study aims to determine if combining these medications leads to better improvement in depression symptoms compared to using escitalopram alone. The treatment period lasts for 6 weeks, during which participants take their assigned medications daily. The medications are given as oral tablets or capsules.

Throughout the study, participants’ depression symptoms will be monitored using various assessment tools that measure mood, anxiety, and emotional recognition. The study will also track any side effects that participants may experience, particularly focusing on tiredness, digestive system effects, and headaches.

During the study, participants will receive either PEX010 psilocybin capsules containing 25 milligrams of the active substance or a placebo containing maltodextrin. The maximum treatment period with psilocybin is three weeks, with a total maximum dose of 50 milligrams. The study will monitor changes in depression symptoms and overall mental health for 60 days after starting treatment.

The research will use various methods to track participants’ progress, including assessments of depression severity, anxiety levels, and general mental well-being. Brain activity will be monitored using special imaging techniques called functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) to understand how these treatments affect brain networks involved in depression.

The purpose of this research is to determine if using flumazenil can reduce memory and thinking-related side effects that can occur with ECT treatment, while still maintaining its effectiveness in treating depression. The study will also look at how this approach affects the brain’s memory networks. During the study, participants will receive either flumazenil or a placebo through an injection before their ECT sessions.

Throughout the study period, which lasts up to three months, various aspects will be monitored, including memory function, thinking abilities, and how well the treatment works for depression symptoms. The research will also assess how quickly patients recover after each treatment session and their overall satisfaction with the procedure.

The main goal of the study is to assess the safety of using psilocybin-assisted psychotherapy in a hospital setting for those with treatment-resistant depression. Participants will receive the psilocybin treatment while being closely monitored in the hospital. The study will observe how patients respond to the treatment over a period of time, including any changes in their depression symptoms and overall well-being. The study will also look at how feasible it is to provide this type of treatment in a hospital environment.

Throughout the study, participants will have several sessions where they take the psilocybin capsule and engage in psychotherapy. They will be monitored for any side effects and changes in their mental health. The study will also involve follow-up assessments to track the participants’ progress and any improvements in their depression symptoms over time. This research aims to explore new ways to help those who have not benefited from traditional depression treatments.

The purpose of the study is to compare brain inflammation patterns among three groups: those currently experiencing MDD, those who have had MDD but are in remission and still taking antidepressants, and healthy individuals without any history of depression. Participants will undergo imaging tests to observe the distribution of inflammation in the brain. The study aims to provide insights into how inflammation is related to depression and how it differs between those currently experiencing depression, those in remission, and healthy individuals.

Throughout the study, participants will have their brain activity monitored using imaging techniques like MRI (Magnetic Resonance Imaging) to assess brain structure and function. Additionally, various scales will be used to evaluate symptoms of depression, anxiety, and other related conditions. The study will also measure biological markers in the blood to understand the role of inflammation in depression. This research hopes to improve understanding of depression and potentially lead to better treatments in the future.

The purpose of this research is to determine how well these treatments work in reducing depression symptoms when used over an 8-week period. During the study, participants will be divided into different groups, with some receiving melatonin, some receiving light therapy, some receiving both treatments, and others receiving placebo. The treatment period lasts for 8 weeks, with regular check-ups to monitor participants’ progress.

Throughout the study, doctors will assess changes in depression symptoms and sleep patterns. They will use various methods to measure improvements in mood and sleep quality. The total amount of melatonin that participants might receive during the entire study period is 112 mg, taken as daily doses of 2 mg in the form of prolonged-release tablets.

Participants in the study will receive different doses of Wegovy, ranging from 0.25 mg to 2.4 mg, over a period of several weeks. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will monitor changes in depressive symptoms using a questionnaire called the Major Depression Inventory, which helps assess the severity of depression symptoms over time.

In addition to evaluating mood changes, the study will also look at other health factors such as body weight, waist and hip measurements, blood sugar levels, and overall quality of life. The goal is to understand how semaglutide affects both mental and physical health in individuals with depression and weight concerns. The study is expected to continue until 2027, providing valuable insights into the potential benefits of semaglutide for this group of patients.

The purpose of the study is to understand how p-glycoprotein is involved in treatment-resistant depression by comparing its activity in people with this condition to those whose depression responds to treatment. Participants will receive an injection of [18F]MC225, and then undergo a PET scan to measure how the radiotracer is distributed in the brain. This will help researchers see if there are differences in p-glycoprotein activity between the two groups.

The study will take place over a period of time, during which participants will be asked to come in for the PET scan and possibly other assessments related to their depression. The information gathered from this study could provide valuable insights into why some people with depression do not respond to standard treatments and help in developing better treatment strategies in the future.

The purpose of the study is to evaluate how effective psilocybin is in treating individuals with treatment-resistant depression. Participants in the study will receive psilocybin over a period of four weeks. The study will monitor changes in the severity of depression symptoms, using a standard questionnaire called the Beck Depression Inventory II, one week after the treatment period ends.

Psilocybin is a chemical substance that is being researched for its potential therapeutic benefits in mental health conditions. The study aims to provide insights into whether psilocybin can offer relief for those who have not found success with traditional antidepressant treatments. The trial is expected to continue until 2026, allowing researchers to gather comprehensive data on its effects.

Participants in the study will receive either the combination of ketamine and ECT or a standard treatment, which may include a placebo. The study will last for several weeks, during which participants will undergo regular assessments to monitor changes in their depressive symptoms. These assessments will help determine the short-term and long-term effects of the treatment. The primary focus will be on the change in symptoms from the start of the study to the end of the fourth week, using a scale called the Montgomery-Åsberg Depression Rating Scale (MADRS). This scale is commonly used to measure the severity of depression.

In addition to evaluating changes in depressive symptoms, the study will also look at how the treatment affects cognitive function, which includes mental processes like thinking, memory, and problem-solving. These cognitive assessments will be conducted at the end of the fourth week and again at the twelfth week to understand the broader impact of the treatment. The study aims to provide valuable insights into the potential benefits of combining ketamine with ECT for individuals with treatment-resistant depression.

The trial will also explore whether it is possible to predict how well a patient will respond to ECT using clinical characteristics and EEG (a test that measures electrical activity in the brain). This could help avoid unnecessary ECT treatments for those unlikely to benefit from it. Participants in the study will receive either the Rivastigmine patch or a placebo patch, which looks the same but contains no active medication. The study will monitor changes in cognitive abilities and other health measures over time to assess the effectiveness of Rivastigmine.

By participating in this study, researchers hope to develop a method to predict ECT response and reduce its cognitive side effects, potentially improving the quality of life for patients with severe depression. The study will also investigate various factors, such as speech patterns and changes in blood and DNA, to see if they can predict the effects of ECT and Rivastigmine. The ultimate goal is to create a comprehensive prediction method to enhance treatment outcomes for depression.

Participants in the study will receive either the vitamin D supplement or a placebo. The trial will monitor changes in the severity of depression symptoms using a tool called the Montgomery-Asberg Depression Rating Scale (MADRS). The study will also track the time it takes for symptoms to improve significantly. Additionally, the study will measure changes in vitamin D levels in the body at both 12 and 24 weeks.

The goal of this research is to understand whether vitamin D supplementation can be an effective treatment option for people with depressive or bipolar disorders. By participating in this study, researchers hope to gather valuable information that could lead to better treatment strategies for these conditions in the future.

The purpose of the study is to assess how effective choline alfoscerate is in treating subthreshold depression in people aged 65 and older. Participants in the study will take the medication orally, and the study will last for a period of up to eight weeks. During this time, the effects of the medication on depression symptoms will be monitored and evaluated. The study aims to provide insights into whether this treatment can be beneficial for older adults experiencing mild depression symptoms.

Throughout the study, participants will undergo various assessments to track changes in their depression symptoms. These assessments will help determine if there is an improvement in their condition after taking the medication. The study is designed to gather important information that could lead to better treatment options for elderly individuals with subthreshold depression.

The purpose of the study is to understand how sertraline affects anxiety and depression symptoms, as well as certain heart-related health markers, in people with this type of heart failure. Participants will be monitored over a period of time to see if there are any changes in their symptoms or health status. The study will also look at how sertraline might impact the time it takes for participants to be hospitalized for heart-related issues or any other cause, as well as the time to any cause of death.

Throughout the study, participants will undergo regular assessments to track their mental health using tools like the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) scale. These assessments will help determine any changes in anxiety and depression levels. Additionally, the study will evaluate other health indicators, such as biomarkers related to the function of blood vessels, to gain a comprehensive understanding of sertraline’s effects on heart health and mental well-being in these patients.

The study will last for a period of 14 days, during which participants will take the medication in the form of a hard capsule by mouth. The effects of the treatment will be monitored by assessing the severity of depression symptoms using a tool called the Hamilton Scale for Depression (HAMD-21). This assessment will be conducted several times throughout the study to track any changes in symptoms.

The purpose of this study is to determine if adding etifoxine hydrochloride to the usual treatment can speed up the improvement of depression symptoms compared to adding a placebo. Participants will be closely monitored for any changes in their condition and any side effects that may occur during the study period.

Participants in the study will receive psilocybin and undergo brain scans using a technique called fMRI (functional Magnetic Resonance Imaging) to observe changes in brain activity before and after the treatment. The study will also monitor changes in depression symptoms and overall mood over time, with assessments conducted at various intervals, including the start of the study, four days later, and then one and three months after treatment. Additionally, participants will provide feedback on their experience during the treatment sessions, including any side effects or issues with tolerance.

The study aims to gather valuable information on how psilocybin might help improve symptoms of depression by examining both brain activity and changes in mood and behavior. This research could potentially lead to new treatment options for those who have not found relief with existing antidepressant medications.

The purpose of the study is to evaluate how effective psilocybin is in treating depression in patients who also have cancer, compared to ketamine and midazolam. Participants will receive one of these substances in the form of a hard capsule taken by mouth. The study will last for several weeks, during which participants will be monitored to see how their symptoms change over time. The study will include regular check-ins to assess mood and overall well-being, using various scales and questionnaires to measure changes in depression and quality of life.

Throughout the study, participants will have the opportunity to enter an open extension phase, where they may continue to receive treatment. The study aims to provide insights into how these substances can help improve the mental health of individuals dealing with the dual challenges of depression and cancer. The findings could potentially lead to new treatment options for those affected by these conditions.

The purpose of this study is to evaluate how depressive symptoms change when patients receive either KALINOX or medical air through inhalation. The treatment involves breathing the assigned medical gas through a face mask for up to 60 minutes. The study will monitor changes in depression symptoms at various times after treatment – specifically at 2 hours, 24 hours, and then at one and two weeks after receiving the gas.

During the study, participants will undergo various assessments including MRI scans to examine brain structure and function. The research will also use specialized scales to measure depression severity and monitor any potential side effects. The study uses a method where neither the patient nor the doctor knows which gas is being administered to ensure unbiased results.

The study is divided into two phases. In the first phase, lasting eight weeks, patients receive either oral esketamine or ECT treatment. The second phase extends for one year and examines how well these treatments prevent the depression from returning in patients who showed improvement during the first phase.

During the treatment period, patients initially receive care in a hospital setting and then continue their treatment as outpatients. The medication being tested, esketamine, is a modified version of an existing injectable solution that has been adapted for oral use by adding ingredients to make it suitable for taking by mouth. The maximum daily dose of esketamine is 3.0 mg per kilogram of body weight, and treatment can continue for up to 60 days.

Participants in the study will receive treatments through intravenous infusion, which means the medication is given directly into a vein. The study will compare the effects of ketamine with those of a placebo to see if there is a significant difference in how well the depression symptoms improve. The trial will also look at changes in alcohol cravings and consumption, as well as any side effects that may occur during the treatment sessions.

The study will take place over a period of time, with participants being monitored for changes in their symptoms and overall health. The goal is to gather information on how ketamine can help people with both depression and alcohol use disorder, and to understand its impact on their mental health and alcohol consumption habits. This research aims to provide valuable insights into potential new treatment options for individuals facing these challenges.

The purpose of the study is to determine if the combination of ketamine and CBASP can lead to a greater reduction in depressive symptoms compared to the other treatment combinations. The study will last for several weeks, during which participants will receive their assigned treatments and have their symptoms monitored. The main goal is to see if there is a noticeable improvement in depression symptoms from the start of the treatment to six weeks after the treatment ends.

Throughout the study, participants’ depressive symptoms will be assessed using a standardized tool called the Montgomery–Åsberg Depression Rating Scale (MADRS). This scale is widely used by clinicians to evaluate the severity of depression. The assessments will be conducted by a person who is not involved in the treatment to ensure unbiased results. The study aims to provide valuable insights into the potential benefits of ketamine as part of a treatment plan for chronic depression.

Participants in the study will receive either ketamine or a placebo, along with venlafaxine, while they are hospitalized for their depressive episode. The study will also use a special imaging technique called PET-MRI to look at changes in the brain before and after the treatment. This will help researchers understand if improvements in depression symptoms are linked to changes in the brain. The study will last for a short period, with the main focus on the first two weeks of treatment.

In addition to monitoring changes in depression symptoms, the study will also look at other factors such as the length of hospital stay and any side effects that may occur. The safety of ketamine will be closely monitored, especially during and shortly after its administration. This research aims to provide more information on how ketamine can be used effectively and safely as part of a treatment plan for severe depression.

Participants in the study will continue their regular depression treatment while also taking either dexamethasone or a placebo for a short period. The study will monitor changes in depression symptoms and overall well-being over several weeks. The goal is to determine if dexamethasone can safely and effectively enhance the treatment of depression. The study will also look at various aspects of participants’ health, including any side effects, changes in mood, and quality of life.

In addition to dexamethasone, the study involves several other medications commonly used to treat depression, such as mirtazapine, citalopram, escitalopram, nortriptyline, sertraline, venlafaxine, lithium, and quetiapine. These medications are part of the usual treatment for depression and will be continued as prescribed by the participants’ healthcare providers. The study aims to provide valuable insights into how dexamethasone might be used alongside these treatments to improve outcomes for people with depression.

The purpose of the study is to compare two different methods of gradually reducing the dose of these medications to see which one is more effective in helping patients stop their medication without experiencing a return of their depression symptoms. Participants will follow a specific schedule to slowly decrease their medication over a period of time. The study will monitor how many participants are able to successfully stop their medication and how many need to restart it within 16 weeks after stopping.

Throughout the study, participants will be observed for any withdrawal symptoms, which are physical or emotional symptoms that can occur when stopping a medication. The study will also track any signs of depression or anxiety returning. The goal is to find a safe and effective way to discontinue antidepressants for those who are ready to stop taking them. Participants will be supported by healthcare professionals throughout the process to ensure their safety and well-being.

Participants in the study will either receive the OSU6162 tablet or a placebo, which looks like the real medication but does not contain the active substance. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for a period of up to 10 weeks, during which the effects of the treatment will be closely monitored.

The main goal is to see if adding OSU6162 can help reduce the symptoms of depression in those who have not responded well to their current medications. The study will measure changes in depression symptoms using a specific scale known as the Hamilton Depression Rating Scale. This trial aims to provide valuable information on whether OSU6162 can be a beneficial addition to existing treatments for depression.